Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Jan 12;1(1):CD010447.
doi: 10.1002/14651858.CD010447.pub3.

Pharmacological treatment of vascular risk factors for reducing mortality and cardiovascular events in patients with abdominal aortic aneurysm

Lindsay Robertson  1 , Edmond Atallah  2 , Gerard Stansby  3
Affiliations

Pharmacological treatment of vascular risk factors for reducing mortality and cardiovascular events in patients with abdominal aortic aneurysm

Lindsay Robertson et al. Cochrane Database Syst Rev. .

Abstract

Background: Pharmacological prophylaxis has been proven to reduce the risk of cardiovascular events in individuals with atherosclerotic occlusive arterial disease. However, the role of prophylaxis in individuals with abdominal aortic aneurysm (AAA) remains unclear. Several studies have shown that despite successful repair, those people with AAA have a poorer rate of survival than healthy controls. People with AAA have an increased prevalence of coronary heart disease and risk of cardiovascular events. Despite this association, little is known about the effectiveness of pharmacological prophylaxis in reducing cardiovascular risk in people with AAA. This is an update of a Cochrane review first published in 2014.

Objectives: To determine the long-term effectiveness of antiplatelet, antihypertensive or lipid-lowering medication in reducing mortality and cardiovascular events in people with abdominal aortic aneurysm (AAA).

Search methods: For this update the Cochrane Vascular Information Specialist (CIS) searched the Cochrane Vascular Specialised Register (14 April 2016). In addition, the CIS searched the Cochrane Central Register of Controlled Trials (CENTRAL) (2016, Issue 3) and trials registries (14 April 2016) and We also searched the reference lists of relevant articles.

Selection criteria: Randomised controlled trials in which people with AAA were randomly allocated to one prophylactic treatment versus another, a different regimen of the same treatment, a placebo, or no treatment were eligible for inclusion in this review. Primary outcomes included all-cause mortality and cardiovascular mortality.

Data collection and analysis: Two review authors independently selected studies for inclusion, and completed quality assessment and data extraction. We resolved any disagreements by discussion. Only one study met the inclusion criteria of the review, therefore we were unable to perform meta-analysis.

Main results: No new studies met the inclusion criteria for this update. We included one randomised controlled trial in the review. A subgroup of 227 participants with AAA received either metoprolol (N = 111) or placebo (N = 116). There was no clear evidence that metoprolol reduced all-cause mortality (odds ratio (OR) 0.17, 95% confidence interval (CI) 0.02 to 1.41), cardiovascular death (OR 0.20, 95% CI 0.02 to 1.76), AAA-related death (OR 1.05, 95% CI 0.06 to 16.92) or increased nonfatal cardiovascular events (OR 1.44, 95% CI 0.58 to 3.57) 30 days postoperatively. Furthermore, at six months postoperatively, estimated effects were compatible with benefit and harm for all-cause mortality (OR 0.71, 95% CI 0.26 to 1.95), cardiovascular death (OR 0.73, 95% CI 0.23 to 2.39) and nonfatal cardiovascular events (OR 1.41, 95% CI 0.59 to 3.35). Adverse drug effects were reported for the whole study population and were not available for the subgroup of participants with AAA. We considered the study to be at a generally low risk of bias. We downgraded the quality of the evidence for all outcomes to low. We downgraded the quality of evidence for imprecision as only one study with a small number of participants was available, the number of events was small and the result was consistent with benefit and harm.

Authors' conclusions: Due to the limited number of included trials, there is insufficient evidence to draw any conclusions about the effectiveness of cardiovascular prophylaxis in reducing mortality and cardiovascular events in people with AAA. Further good-quality randomised controlled trials that examine many types of prophylaxis with long-term follow-up are required before firm conclusions can be made.

PubMed Disclaimer

Conflict of interest statement

LR: none known EA: none known GS: none known

Figures

1
1
Study flow diagram.
2
2
'Risk of bias' summary: review authors' judgements about each 'Risk of bias' item for each included study.
1.1
1.1. Analysis
Comparison 1 Metoprolol versus placebo, Outcome 1 All‐cause mortality, 30 days.
1.2
1.2. Analysis
Comparison 1 Metoprolol versus placebo, Outcome 2 Cardiovascular death, 30 days.
1.3
1.3. Analysis
Comparison 1 Metoprolol versus placebo, Outcome 3 AAA‐related death, 30 days.
1.4
1.4. Analysis
Comparison 1 Metoprolol versus placebo, Outcome 4 Nonfatal cardiovascular event, 30 days.
1.5
1.5. Analysis
Comparison 1 Metoprolol versus placebo, Outcome 5 All‐cause mortality, 6 months.
1.6
1.6. Analysis
Comparison 1 Metoprolol versus placebo, Outcome 6 Cardiovascular death, 6 months.
1.7
1.7. Analysis
Comparison 1 Metoprolol versus placebo, Outcome 7 Nonfatal cardiovascular event, 6 months.
See this image and copyright information in PMC

Update of

References

References to studies included in this review

Yang 2006 {published data only}
    1. Yang H, Raymer K, Butler R, Parlow J, Roberts R. The effects of perioperative β‐blockade: results of the Metoprolol after Vascular Surgery (MaVS) study, a randomized controlled trial. American Heart Journal 2006;152(5):983‐90. - PubMed
    1. Yang H, Raymer K, Butler R, Parlow J, Roberts R, Tech M. Metoprolol after vascular surgery. Canadian Journal of Anaesthesia 2004;51(Suppl 1):A7.

References to studies excluded from this review

Ashes 2013 {published data only}
    1. Ashes C, Judelman S, Wijeysundera DN, Tait G, Mazer CD, Hare GM, et al. Selective ß1‐antagonism with bisoprolol is associated with fewer postoperative strokes than atenolol or metoprolol: a single‐center cohort study of 44,092 consecutive patients. Anesthesiology 2013;119(4):777‐87. - PubMed
Berwanger 2015 {published data only}
    1. Berwanger O, Soares RM, Ikeoka DT, Paisani DM, Silva BG, Bernardez‐Pereira S, et al. Atorvastatin for the prevention of major vascular events in patients undergoing non‐cardiac surgery: the load‐pilot randomized clinical trial. Circulation 2015;132:A13635.
Cesanek 2008 {published data only}
    1. Cesanek P, Schwann N, Wilson E, Urffer S, Maksimik C, Nabhan S, et al. The effect of beta‐blocker dosing strategy on regulation of perioperative heart rate and clinical outcomes in patients undergoing vascular surgery: a randomized comparison. Annals of Vascular Surgery 2008;22(5):643‐8. - PubMed
DECREASE Study {published data only}
    1. Bakker EJ, Ravensbergen NJ, Voute MT, Hoeks SE, Chonchol M, Klimek M, et al. A randomised study of perioperative esmolol infusion for haemodynamic stability during major vascular surgery: Rationale and design of DECREASE‐XIII. European Journal of Vascular and Endovascular Surgery 2011;42(3):317‐23. - PubMed
    1. Dunkelgrun M, Boersma E, Koopman‐Van Gemert AWMM, Poorten F, Kalkman C, Schouten O, et al. Fluvastatin and bisoprolol for cardiac risk reduction in intermediate‐risk patients undergoing non‐cardiovascular surgery: a randomised controlled trial. European Heart Journal 2008;29(Abstract Suppl):602‐3.
    1. Dunkelgrun M, Boersma E, Schouten O. Koopman‐Van Gemert AWMM, Poorten F, Bax JJ, et al. for the Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echocardiography Study Group. Bisoprolol and fluvastatin for the reduction of perioperative cardiac mortality and myocardial infarction in intermediate‐risk patients undergoing noncardiovascular surgery: a randomised controlled trial (DECREASE‐IV). Annals of Surgery 2009;249(6):921‐6. - PubMed
    1. Flu WJ, Kujik JP, Chonchol M, Winkel TA, Verhagen HJ, Bax JJ, et al. Timing of perioperative Beta‐blocker treatment in vascular surgery patients: influence on post‐operative outcome. Journal of the American College of Cardiology 2010;56(23):1922‐9. - PubMed
    1. Hoeks SE, Schouten O, Dunkelgrun M, Lier F, Durazzo AE, Neskovich AN, et al. Perioperative stroke in non‐cardiac surgery; the impact of prophylactic beta‐blocker therapy. European Heart Journal 2008;29(Abstract Supplement):395.
Durazzo 2004 {published data only}
    1. Caramelli B, Durazzo A, Ikeoka D, Bernoche C, Monachini M, Puech LP, et al. Short‐term treatment with atorvastatin for prevention of cardiac complications after vascular surgery. Abstract No 086. Atherosclerosis Supplements 2002;3:83.
    1. Durazzo AE, Machado FS, Ikeoka D, Puech LP, Caramelli B. Effect of atorvastatin on cardiovascular events after vascular surgery. Circulation 2002;106(II):343.
    1. Durazzo AE, Machado FS, Ikeoka DT, Bernoche C, Monachini MC, Puech‐Leao P, et al. Reduction in cardiovascular events after vascular surgery with atorvastatin: a randomised trial. Journal of Vascular Surgery 2004;39(5):967‐75. - PubMed
Kouvelos 2011 {published data only}
    1. Kouvelos G, Milionis H, Arnaoutoglou E. The effect of intensified lipid lowering therapy on one‐year prognosis in patients undergoing vascular surgery. Interactive Cardiovascular and Thoracic Surgery 2011;12:S61‐2.
Kouvelos 2013 {published data only}
    1. Kouvelos GN, Arnaoutoglou EM, Matsagkas MI, Kostara C, Gartzonika C, Bairaktari ET, et al. Effects of rosuvastatin with or without ezetimibe on clinical outcomes in patients undergoing elective vascular surgery: results of a pilot study. Journal of Cardiovascular Pharmacology and Therapeutics 2013;18(1):5‐12. - PubMed
    1. Kouvelos GN, Arnaoutoglou EM, Milionis HJ, Raikou VD, Papa N, Matsagkas MI. The effect of adding ezetimibe to rosuvastatin on renal function in patients undergoing elective vascular surgery. Angiology 2015;66(2):128‐35. - PubMed
Mackey 2006 {published data only}
    1. Mackey WC, Fleisher LA, Haider S, Sheikh S, Cappalleri JC, Lee WC, et al. Perioperative myocardial ischemic injury in high‐risk vascular surgery patients: incidence and clinical significance in a prospective clinical trial. Journal of Vascular Surgery 2006;43(3):533‐8. - PubMed
Mangano 1996 {published data only}
    1. Mangano DT, Layug EL, Wallace A, Tateo I, for the Multicentre Study of Perioperative Ischemia Research Group. Effect of atenolol on mortality and cardiovascular morbidity after noncardiac surgery. New England Journal of Medicine 1996;335(23):1713‐20. - PubMed
NCT01225094 {published data only}
    1. NCT01225094. Curcumin to prevent complications after elective abdominal aortic aneurysm (AAA) repair. clinicaltrials.gov/ct2/show/NCT01225094 (first received 19 October 2010).
Neilipovitz 2012 {published data only}
    1. Neilipovitz DT, Bryson GL, Taljaard M. STAR VaS‐‐Short term atorvastatin regime for vasculopathic subjects: a randomized placebo‐controlled trial evaluating perioperative atorvastatin therapy in noncardiac surgery. Canadian Journal of Anaesthesia 2012;59(6):527‐37. - PubMed
POBBLE Trial {published data only}
    1. Brady AR, Gibbs JS, Greenhalgh RM, Powell JT, Sydes MR, POBBLE trial investigators. Perioperative beta‐blockade (POBBLE) for patients undergoing infrarenal vascular surgery: results of a randomized double‐blind controlled trial. Journal of Vascular Surgery 2005;41(4):602‐9. - PubMed
    1. Schouten O, Urk H, Feringa HH, Bax JJ, Poldermans D. Regarding "Perioperative beta‐blockade (POBBLE) for patients undergoing infrarenal vascular surgery: results of a randomized double‐blind controlled trial" [comment]. Journal of Vascular Surgery 2005;42(4):825, author reply 826. - PubMed
POISE Study {published data only}
    1. Devereaux PJ . The perioperative ischemic evaluation (POISE) trial: a randomized controlled trial of metoprolol versus placebo in patients undergoing noncardiac surgery. Clinical Research in Cardiology 2008;97(1):8. - PubMed
    1. POISE Trial Investigators: Devereaux PJ, Yang H, Guyatt GH, Leslie K, Villar JC, Monteri VM, et al. Rationale, design, and organization of the PeriOperative ISchemic Evaluation (POISE) trial: a randomized controlled trial of metoprolol versus placebo in patients undergoing noncardiac surgery. American Heart Journal 2006;152(2):223‐30. - PubMed
    1. POISE study group, Devereaux PJ, Yang H, Yusuf S, Guyatt G, Leslie K, et al. Effects of extended‐release metoprolol succinate in patients undergoing non‐cardiac surgery (POISE trial): a randomised controlled trial. Lancet 2008;371(9627):1839‐47. - PubMed
Qu 2014 {published data only}
    1. Qu Y, Wei L, Zhang H. Inhibition of inflammation mediates the protective effect of atorvastatin reload in patients with coronary artery disease undergoing noncardiac emergency surgery. Coronary Artery Disease 2014;25(8):678‐84. - PubMed
Schouten 2011 {published data only}
    1. Schouten O, Hoeks SE, Boersma H. Long‐term outcome of the DECREASE III trial; the impact of initiation of statin therapy prior to surgery. European Heart Journal 2011;32:332‐3.
Xia 2014 {published data only}
    1. Xia J, Qu Y, Shen H, Liu X. Patients with stable coronary artery disease receiving chronic statin treatment who are undergoing noncardiac emergency surgery benefit from acute atorvastatin reload. Cardiology 2014;128(3):285‐92. - PubMed
Xia 2015 {published data only}
    1. Xia J, Qu Y, Yin C, Xu D. Preoperative rosuvastatin protects patients with coronary artery disease undergoing noncardiac surgery. Cardiology 2015;131(1):30‐7. - PubMed

Additional references

Atkins 2004
    1. Atkins D, Best D, Briss PA, Eccles M, Falck‐Ytter Y, Flottorp S, et al. GRADE Working Group. Grading quality of evidence and strength of recommendations. BMJ 2004;328(7454):1490‐4. - PMC - PubMed
Badger 2009
    1. Badger SA, O'Donnell ME, Sharif MA, McMaster C, Young IS, Soong CV. The role of smoking in abdominal aortic aneurysm development. Angiology 2009;60(1):115‐9. - PubMed
Badger 2014
    1. Badger S, Bedenis R, Blair PH, Ellis P, Kee F, Harkin DW. Endovascular treatment for ruptured abdominal aortic aneurysm. Cochrane Database of Systematic Reviews 2014, Issue 7. [DOI: 10.1002/14651858.CD005261.pub3] - DOI - PubMed
Blanchard 2000
    1. Blanchard JF, Armenian HK, Friesen PP. Risk factors for abdominal aortic aneurysm: results of a case‐control study. American Journal of Epidemiology 2000;151(6):575‐83. - PubMed
Bolsin 2013
    1. Bolsin S, Colson M, Marsiglio A. Perioperative ß‐blockade. BMJ 2013;347:f5640. - PubMed
Brown 1999
    1. Brown LC, Powell JT. Risk factors for aneurysm rupture in patients kept under ultrasound surveillance. UK Small Aneurysm Trial Participants. Annals of Surgery 1999;230(3):289‐96. - PMC - PubMed
Brown 2011
    1. Brown LC, Thompson SG, Greenhalgh RM, Powell JT, Endovascular Aneurysm Repair trial participants. Incidence of cardiovascular events and death after open or endovascular repair of abdominal aortic aneurysm in the randomized EVAR trial 1. British Journal of Surgery 2011;98(7):935‐42. - PubMed
Davis 2008
    1. Davis M, Taylor PR. Endovascular infrarenal abdominal aortic aneurysm repair. Heart 2008;94(2):222‐8. - PubMed
de Bruin 2014
    1. Bruin JL, Baas AF, Heymans MW, Buimer MG, Prinssen M, Grobbee DE, et al. Statin therapy is associated with improved survival after endovascular and open aneurysm repair. Journal of Vascular Surgery 2014;59(1):39‐44.e1. - PubMed
De Martino 2013
    1. Martino RR, Goodney PP, Nolan BW, Robinson WP, Farber A, Patel VI, et al. Optimal selection of patients for elective abdominal aortic aneurysm repair based on life expectancy. Journal of Vascular Surgery 2013;58(3):589‐95. - PMC - PubMed
Deeks 2011
    1. Deeks JJ, Higgins JPT, Altman DG. Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Erasmus MC Follow‐Up Committee 2012
    1. Erasmus MC Follow‐up Investigation Committee. Report on the 2012 follow‐up investigation of possible breaches of academic integrity. 30 September 2012. http://www.erasmusmc.nl/5663/135857/3675250/3706798/Integrity_report_201... (accessed 10 April 2013).
Filardo 2015
    1. Filardo G, Powell JT, Martinez MA, Ballard DJ. Surgery for small asymptomatic abdominal aortic aneurysms. Cochrane Database of Systematic Reviews 2015, Issue 2. [DOI: 10.1002/14651858.CD001835.pub4] - DOI - PMC - PubMed
GRADEpro GDT 2014 [Computer program]
    1. GRADE Working Group, McMaster University. GRADEpro GDT. Version accessed 14 October 2016. Hamilton (ON): GRADE Working Group, McMaster University, 2014.
Greenhalgh 2004
    1. Greenhalgh RM, Brown LC, Kwong GP, Powell JT, Thompson SG, EVAR trial participants. Comparison of endovascular aneurysm repair with open repair in patients with abdominal aortic aneurysm (EVAR trial 1), 30‐day operative mortality results: randomised controlled trial. Lancet 2004;364(9437):843‐8. - PubMed
Greenhalgh 2008
    1. Greenhalgh RM, Powell JT. Endovascular repair of abdominal aortic aneurysm. New England Journal of Medicine 2008;358(5):494‐501. - PubMed
Hackam 2006
    1. Hackam DG, Thiruchelvam D, Redelmeier DA. Angiotensin‐converting enzyme inhibitors and aortic rupture: a population‐based case‐control study. Lancet 2006;368(9536):659‐65. - PubMed
Higgins 2011
    1. Higgins JPT, Altman DG, Sterne JAC. Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Hirsch 2005
    1. Hirsch AT, Haskal ZJ, Hertzer NR, Bakal CW, Creager MA, Halperin JL, et al. ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and ACC/AHA Task Force on Practice Guidelines: endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter‐Society Consensus; and Vascular Disease Foundation. Circulation 2006;113(11):e463‐e654. - PubMed
Kertai 2004
    1. Kertai MD, Boersma E, Westerhout CM, Domburg R, Klein J, Bax JJ, et al. Association between long‐term statin use and mortality after successful abdominal aortic aneurysm surgery. American Journal of Medicine 2004;116(2):96‐103. - PubMed
Lloyd 2010
    1. Lloyd‐Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, Simone G, et al. on behalf of the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics‐‐2010 update: a report from the American Heart Association. Circulation 2010;121(7):e46‐e215. - PubMed
Morange 2006
    1. Morange PE, Bickel C, Nicaud V, Schnabel R, Rupprecht HJ, Peetz D, et al. AtheroGene Investigators. Haemostatic factors and the risk of cardiovascular death in patients with coronary artery disease: the AtheroGene study. Arteriosclerosis, Thrombosis, and Vascular Biology 2006;26(12):2793‐9. - PubMed
Ohrlander 2011
    1. Ohrlander T, Dencker M, Dias NV, Gottsäter A, Acosta S. Cardiovascular predictors for long‐term mortality after EVAR for AAA. Vascular Medicine 2011;16(6):422‐7. - PubMed
Paravastu 2014
    1. Paravastu SCV, Jayarajasingam R, Cottam R, Palfreyman SJ, Michaels JA, Thomas SM. Endovascular repair of abdominal aortic aneurysm. Cochrane Database of Systematic Reviews 2014, Issue 1. [DOI: 10.1002/14651858.CD004178.pub2] - DOI - PMC - PubMed
Parr 2011
    1. Parr A, McCann M, Bradshaw B, Shahzad A, Buttner P, Golledge J. Thrombus volume is associated with cardiovascular events and aneurysm growth in patients who have abdominal aortic aneurysms. Journal of Vascular Surgery 2011;53(1):28‐35. - PMC - PubMed
Parry 2009
    1. Parry DJ, Al‐Barjas HS, Chappell L, Rashid T, Ariëns RA, Scott DJ. Haemostatic and fibrinolytic factors in men with a small abdominal aortic aneurysm. British Journal of Surgery 2009;96(8):870‐7. - PubMed
Pleumeekers 1995
    1. Pleumeekers HJCM, Hoes AW, Does E, Urk H, Hofman A, Jong PTVM, et al. Aneurysms of the abdominal aorta in older adults. The Rotterdam Study. American Journal of Epidemiology 1995;142(12):1291–9 . - PubMed
Prinssen 2004
    1. Prinssen M, Verhoeven ELG, Buth J, Cuypers PWM, Sambeek MR, Balm R, et al. for the Dutch Randomized Endovascular Aneurysm Management (DREAM) Trial Group. A randomized trial comparing conventional and endovascular repair of abdominal aortic aneurysms. New England Journal of Medicine 2004;351(16):1607‐18. - PubMed
RevMan 2014 [Computer program]
    1. Nordic Cochrane Centre, the Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, the Cochrane Collaboration, 2014.
Rughani 2012
    1. Rughani G, Robertson L, Clarke M. Medical treatment for small abdominal aortic aneurysms. Cochrane Database of Systematic Reviews 2012, Issue 9. [DOI: 10.1002/14651858.CD009536.pub2] - DOI - PMC - PubMed
Schouten 2006
    1. Schouten O, Kok NF, Hoedt MT, van Laanen JH, Poldermans D. The influence of aneurysm size on perioperative cardiac outcome in elective open infrarenal aortic aneurysm repair. Journal of Vascular Surgery 2006;44(3):435‐41. - PubMed
Scott 2002
    1. Scott RA, Bridgewater SG, Ashton HA. Randomized clinical trial of screening for abdominal aortic aneurysm in women. British Journal of Surgery 2002;89(3):283‐5. - PubMed
Singh 2001
    1. Singh K, Bønaa KH, Jacobsen BK, Bjørk L, Solberg S. Prevalence of and risk factors for abdominal aortic aneurysms in a population‐based study. The Tromsø Study. American Journal of Epidemiology 2001;154(3):236‐44. - PubMed
Smith 2005
    1. Smith A, Patterson C, Yarnell J, Rumley A, Ben‐Schlomo Y, Lowe G. Which hemostatic markers add to the predictive value of conventional risk factors for coronary heart disease and ischemic stroke? The Caerphilly study. Circulation 2005;112(20):3080‐7. - PubMed
Sterne 2011
    1. Sterne JAC, Egger M, Moher D. Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Takagi 2009
    1. Takagi H, Manabe H, Kawai N, Goto S, Umemoto T. Plasma fibrinogen and D‐dimer concentrations are associated with the presence of abdominal aortic aneurysm: a systematic review and meta‐analysis. European Journal of Vascular and Endovascular Surgery 2009;38(3):273‐7. - PubMed
Timmers 2013
    1. Timmers TK, Herwaarden JA, Borst GJ, Moll FL, Leenen LP. Long‐term survival and quality of life after open abdominal aortic aneurysm repair. World Journal of Surgery 2013;37(12):2957‐6. - PubMed
van Vlijmen‐van Keulen 2002
    1. Vlijmen‐van Keulen CJ, Pals G, Rauwerda JA. Familial abdominal aortic aneurysm: a systematic review of a genetic background. European Journal of Vascular and Endovascular Surgery 2002;24(2):105‐16. - PubMed
Wanhainen 2008
    1. Wanhainen A. How to define an abdominal aortic aneurysm‐‐influence on epidemiology and clinical practice. Scandinavian Journal of Surgery 2008;97(2):105‐9, discussion 109. - PubMed
Wilmink 1999
    1. Wilmink TB, Quick CR, Day NE. The association between cigarette smoking and abdominal aortic aneurysms. Journal of Vascular Surgery 1999;30(6):1099‐105. - PubMed

References to other published versions of this review

Robertson 2013
    1. Robertson L, Atallah E, Stansby G. Pharmacological treatment of vascular risk factors for reducing mortality and cardiovascular events in patients with abdominal aortic aneurysm. Cochrane Database of Systematic Reviews 2013, Issue 3. [DOI: 10.1002/14651858.CD010447] - DOI
Robertson 2014
    1. Robertson L, Atallah E, Stansby G. Pharmacological treatment of vascular risk factors for reducing mortality and cardiovascular events in patients with abdominal aortic aneurysm. Cochrane Database of Systematic Reviews 2014, Issue 1. [DOI: 10.1002/14651858.CD010447.pub2] - DOI - PubMed

Publication types

MeSH terms